Literature DB >> 27844209

The impact of parathyroidectomy on serum ADAMTS1, ADAMTS4 levels, insulin resistance, and subclinical cardiovascular disease in primary hyperparathyroidism.

Melia Karakose1, Mustafa Caliskan2, Muyesser Sayki Arslan2, Taner Demirci2, Suleyman Karakose3, Erman Cakal2.   

Abstract

PURPOSE: Primary hyperparathyroidism has been associated with increased incidence of morbidity and mortality of the cardiovascular system. The etiopathogenetic mechanisms underlying this association are still not completely clear. Accumulating evidence suggested that a disintegrin and metalloproteinase with thrombospondin-like motifs (ADAMTS) has a role in the development of inflammation and atherosclerosis. In this study, we aimed to determine whether there is a change in serum levels of ADAMTS1, ADAMTS4, carotid intima-media thickness, and cardiovascular risk score after the surgery and also whether there is a relationship between ADAMTS levels and cardiovascular risk score in hypercalcemic primary hyperparathyroidism patients.
METHODS: The study included the 48 consecutive newly diagnosed patients with primary hyperparathyroidism. The patients were evaluated before and six months after parathyroidectomy. The Framingham score is used to calculate cardiovascular risk. Serum ADAMTS levels were determined by a human enzyme-linked immunoassay in all subjects.
RESULTS: The fasting glucose, fasting insulin levels and HOMA values were decreased significantly in all patients after surgery compared to the pretreatment values (p < 0.05). ADAMTS1, ADAMTS4, and carotid intima-media thickness levels were significantly lower after surgical correction of primary hyperparathyroidism compared to the preoperative values (p < 0.05). cardiovascular risk score was decreased after parathyroidectomy however, the difference were not statistical significant (p > 0.05). There were statistically significant relationship between cardiovascular risk score and waist/hip ratio, calcium, LDL-cholesterol, carotid intima-media thickness, ADAMTS4 values.
CONCLUSION: Based on the results of the present study, fasting glucose, fasting insulin levels, ADAMTS1, ADAMTS4, and carotid intima-media thickness might be an additional parameters during the management of patients with primary hyperparathyroidism, since these factors might improve after surgery.

Entities:  

Keywords:  ADAMTS; Atherosclerosis; Insulin resistance; Parathyroidectomy; Primary hyperparathyroidism

Mesh:

Substances:

Year:  2016        PMID: 27844209     DOI: 10.1007/s12020-016-1175-3

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  35 in total

1.  Serum lipids before and after parathyroidectomy in patients with primary hyperparathyroidism.

Authors:  T Christensson; K Einarsson
Journal:  Clin Chim Acta       Date:  1977-08-01       Impact factor: 3.786

2.  Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older men.

Authors:  Eric Orwoll; Janet Babich Blank; Elizabeth Barrett-Connor; Jane Cauley; Steven Cummings; Kristine Ensrud; Cora Lewis; Peggy M Cawthon; Robert Marcus; Lynn M Marshall; Joan McGowan; Kathy Phipps; Sherry Sherman; Marcia L Stefanick; Katie Stone
Journal:  Contemp Clin Trials       Date:  2005-10       Impact factor: 2.226

Review 3.  Versican degradation and vascular disease.

Authors:  Richard D Kenagy; Anna H Plaas; Thomas N Wight
Journal:  Trends Cardiovasc Med       Date:  2006-08       Impact factor: 6.677

4.  Positive effect of parathyroidectomy on bone mineral density in mild asymptomatic primary hyperparathyroidism.

Authors:  E Hagström; E Lundgren; H Mallmin; J Rastad; P Hellman
Journal:  J Intern Med       Date:  2006-02       Impact factor: 8.989

5.  A 10-year prospective study of primary hyperparathyroidism with or without parathyroid surgery.

Authors:  S J Silverberg; E Shane; T P Jacobs; E Siris; J P Bilezikian
Journal:  N Engl J Med       Date:  1999-10-21       Impact factor: 91.245

Review 6.  Versican: a versatile extracellular matrix proteoglycan in cell biology.

Authors:  Thomas N Wight
Journal:  Curr Opin Cell Biol       Date:  2002-10       Impact factor: 8.382

7.  Impaired glucose tolerance and insulin insensitivity in primary hyperparathyroidism.

Authors:  S Kumar; A O Olukoga; C Gordon; E B Mawer; M France; J P Hosker; M Davies; A J Boulton
Journal:  Clin Endocrinol (Oxf)       Date:  1994-01       Impact factor: 3.478

8.  ADAMTS4 level in patients with stable coronary artery disease and acute coronary syndromes.

Authors:  Yanping Zha; Yong Chen; Fayun Xu; Tian Li; Chuanyan Zhao; Lianqun Cui
Journal:  Biomed Pharmacother       Date:  2009-11-05       Impact factor: 6.529

9.  General cardiovascular risk profile for use in primary care: the Framingham Heart Study.

Authors:  Ralph B D'Agostino; Ramachandran S Vasan; Michael J Pencina; Philip A Wolf; Mark Cobain; Joseph M Massaro; William B Kannel
Journal:  Circulation       Date:  2008-01-22       Impact factor: 29.690

10.  Current issues in the presentation of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop.

Authors:  Shonni J Silverberg; Bart L Clarke; Munro Peacock; Francisco Bandeira; Stephanie Boutroy; Natalie E Cusano; David Dempster; E Michael Lewiecki; Jian-Min Liu; Salvatore Minisola; Lars Rejnmark; Barbara C Silva; Marcella D Walker; John P Bilezikian
Journal:  J Clin Endocrinol Metab       Date:  2014-08-27       Impact factor: 5.958

View more
  9 in total

Review 1.  The intriguing connections of leptin to hyperparathyroidism.

Authors:  Stergios A Polyzos; Leonidas Duntas; Jens Bollerslev
Journal:  Endocrine       Date:  2017-07-20       Impact factor: 3.633

Review 2.  CKD-MBD: from the Pathogenesis to the Identification and Development of Potential Novel Therapeutic Targets.

Authors:  Rosilene Motta Elias; Maria Aparecida Dalboni; Ana Carolina E Coelho; Rosa M A Moysés
Journal:  Curr Osteoporos Rep       Date:  2018-12       Impact factor: 5.096

3.  The effect of surgery on fat mass, lipid and glucose metabolism in mild primary hyperparathyroidism.

Authors:  Kristin Godang; Karolina Lundstam; Charlotte Mollerup; Stine Lyngvi Fougner; Ylva Pernow; Jörgen Nordenström; Thord Rosen; Svante Jansson; Mikael Hellström; Jens Bollerslev; Ansgar Heck
Journal:  Endocr Connect       Date:  2018-07-16       Impact factor: 3.335

4.  Residual risks of comorbidities after parathyroidectomy in a nationwide cohort of patients with primary hyperparathyroidism.

Authors:  Sung Hye Kong; Jung Hee Kim; Man Young Park; Sang Wan Kim; Chan Soo Shin
Journal:  Endocrine       Date:  2022-10-12       Impact factor: 3.925

5.  The influence of parathyroidectomy on cardiometabolic risk factors in patients with primary hyperparathyroidism: a systematic review and meta-analysis.

Authors:  Maryam Yavari; Awat Feizi; Fahimeh Haghighatdoost; Azin Ghaffari; Hassan Rezvanian
Journal:  Endocrine       Date:  2020-10-15       Impact factor: 3.633

Review 6.  Primary hyperparathyroidism and hypertension.

Authors:  Sarah B Fisher; Nancy D Perrier
Journal:  Gland Surg       Date:  2020-02

Review 7.  Recent advances in the understanding and management of primary hyperparathyroidism.

Authors:  Melanie Goldfarb; Frederick R Singer
Journal:  F1000Res       Date:  2020-02-25

8.  Effect of Parathyroidectomy on Metabolic Homeostasis in Primary Hyperparathyroidism.

Authors:  Samuel Frey; Raphaël Bourgade; Cédric Le May; Mikaël Croyal; Edith Bigot-Corbel; Nelly Renaud-Moreau; Matthieu Wargny; Cécile Caillard; Eric Mirallié; Bertrand Cariou; Claire Blanchard
Journal:  J Clin Med       Date:  2022-03-02       Impact factor: 4.241

9.  The effect of surgery on fat mass, lipid and glucose metabolism in mild primary hyperparathyroidism

Authors:  Kristin Godang; Karolina Lundstam; Charlotte Mollerup; Fougner Fougner; Ylva Pernow; Jörgen Nordenström; Thord Rosén; Svante Jansson; Mikael Hellström; Jens Bollerslev; Ansgar Heck
Journal:  Endocr Connect       Date:  2018-08-01       Impact factor: 3.335

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.